Alexion Pharmaceuticals, Inc. (ALXN) said it now expects fiscal 2020 non-GAAP earnings per share in a range of $11.70 to $12.00, revised upward from prior guidance range of $10.65 to $10.95. Total revenues are now projected in a range of $5.90 billion to $5.95 billion, updated from previous guidance range of $5.55 billion to $5.60 billion. Analysts polled by Thomson Reuters expect the company to report profit per share of $11.30 on revenue of $5.75 billion. Analysts' estimates typically exclude special items.
Third quarter non-GAAP earnings per share was $3.24, a 16 percent increase from the third quarter of 2019. On average, 21 analysts expected the company to report profit per share of $2.60, for the quarter.
Third quarter total revenues were $1.59 billion, a 26 percent increase compared to the same period in 2019. Analysts expected revenue of $1.43 billion, for the quarter.
Shares of Alexion Pharmaceuticals, Inc. were up 6% in pre-market trade on Thursday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.